Multiple Sclerosis Therapeutics Market, By Drug Class (Beta Interferon, Corticosteroids, Monoclonal Antibodies, Antineoplastic Agent, Others), By Route of Administration (Oral, Injection, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharm

Multiple Sclerosis Therapeutics Market, By Drug Class (Beta Interferon, Corticosteroids, Monoclonal Antibodies, Antineoplastic Agent, Others), By Route of Administration (Oral, Injection, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)


Multiple sclerosis (MS) is a chronic autoimmune disorder that affects the central nervous system (CNS). It is caused when the immune system attacks myelin, the protective sheath surrounding nerve fibers of the CNS. The damage disrupts communication between the brain and other parts of the body. Symptoms can be mild or severe, depending on the number and location of lesions in the CNS. Common symptoms include fatigue, weakness or numbness in the limbs, poor coordination and balance, vision problems, and cognitive dysfunction. There has been no known cure for MS but medications such as interferons, glatiramer acetate, monoclonal antibodies, corticosteroids can manage the disease symptoms and slow down its progression.

Market Dynamics:

Global multiple sclerosis therapeutics market growth is driven by factors like increasing prevalence of multiple sclerosis across both developed and developing nations, growing geriatric population, robust pipeline of new and innovative treatment therapies for multiple sclerosis, surging healthcare spending, and availability of reimbursement schemes. However, high costs associated with multiple sclerosis drugs can hamper the market growth. Emergence of personalized medicines for multiple sclerosis treatment, growing adoption of combination therapies, infusion therapies, and oral drugs for multiple sclerosis treatment can offer market growth opportunities.

Key features of the study:
  • This report provides in-depth analysis of the global multiple sclerosis therapeutics market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global multiple sclerosis therapeutics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Biogen, Novartis, Merck, Sanofi, Teva Pharmaceuticals, Bayer, ACORDA THERAPEUTICS and CELGENE
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global multiple sclerosis therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global multiple sclerosis therapeutics market

  • Detailed Segmentation-
  • By Drug Class Insights (Revenue, USD Bn, 2019 - 2031)
  • Beta Interferon
  • Corticosteroids
  • Monoclonal Antibodies
  • Antineoplastic Agent
  • Others
  • By Route of Administration Insights (Revenue, USD Bn, 2019 - 2031)
  • Oral
  • Injection
  • Others
  • By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Regional Insights (Revenue, USD Bn, 2019 - 2031)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
  • Key Players Insights
  • Biogen Inc.
  • Novartis AG
  • Merck KGaA
  • Sanofi S. A.
  • Acorda Therapeutics, Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Bristol-Myers Squibb Company
  • Bayer AG
  • Hoffmann-La Roche AG
  • Viatris Inc. (Mylan NV)
  • Johnson & Johnson
  • EMD Serono, Inc.
  • TG Therapeutics, Inc.
  • Genentech, Inc.
  • Celgene Corporation
  • AbbVie Inc.
  • Amgen Inc.
  • UCB S.A.
  • Sandoz (a Novartis division)
  • Ipsen S.A.

  • 1. Research Objectives and Assumptions
    Research Objectives
    Assumptions
    Abbreviations
    2. Market Purview
    Report Description
    Market Definition and Scope
    Executive Summary
    Global Multiple Sclerosis Therapeutics Market, By Drug Class
    Global Multiple Sclerosis Therapeutics Market, By Route of Administration
    Global Multiple Sclerosis Therapeutics Market, By Distribution Channel
    Global Multiple Sclerosis Therapeutics Market, By Region
    3. Market Dynamics, Regulations, and Trends Analysis
    Market Dynamics
    Impact Analysis
    Key Highlights
    Regulatory Scenario
    Product Launches/Approvals
    PEST Analysis
    PORTER’s Analysis
    Merger and Acquisition Scenario
    4. Global Multiple Sclerosis Therapeutics Market, By Drug Class, 2019-2031, (USD Bn)
    Introduction
    Market Share Analysis, 2024 and 2031 (%)
    Y-o-Y Growth Analysis, 2020 - 2031
    Segment Trends
    Beta Interferon
    Introduction
    Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
    Corticosteroids
    Introduction
    Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
    Monoclonal Antibodies
    Introduction
    Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
    Antineoplastic Agent
    Introduction
    Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
    Others
    Introduction
    Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
    5. Global Multiple Sclerosis Therapeutics Market, By Route of Administration, 2019-2031, (USD Bn)
    Introduction
    Market Share Analysis, 2024 and 2031 (%)
    Y-o-Y Growth Analysis, 2020- 2031
    Segment Trends
    Oral
    Introduction
    Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
    Injection
    Introduction
    Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
    Others
    Introduction
    Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
    6. Global Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2019-2031, (USD Bn)
    Introduction
    Market Share Analysis, 2024 and 2031 (%)
    Y-o-Y Growth Analysis, 2020 - 2031
    Segment Trends
    Hospital Pharmacies
    Introduction
    Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
    Retail Pharmacies
    Introduction
    Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
    Online Pharmacies
    Introduction
    Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
    7. Global Multiple Sclerosis Therapeutics Market, By Region, 2019 - 2031, (USD Bn)
    Introduction
    Market Share (%) Analysis, 2024,2027 & 2031, (USD Bn)
    Market Y-o-Y Growth Analysis (%), 2020 - 2031, (USD Bn)
    Regional Trends
    North America
    Introduction
    Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
    Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
    Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
    Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
    U.S.
    Canada
    Latin America
    Introduction
    Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
    Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
    Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
    Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
    Brazil
    Argentina
    Mexico
    Rest of Latin America
    Europe
    Introduction
    Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
    Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
    Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
    Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
    Germany
    U.K.
    Spain
    France
    Italy
    Russia
    Rest of Europe
    Asia Pacific
    Introduction
    Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
    Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
    Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
    Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
    China
    India
    Japan
    Australia
    South Korea
    ASEAN
    Rest of Asia Pacific
    Middle East
    Introduction
    Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
    Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
    Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
    Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
    GCC Countries
    Israel
    Rest of Middle East
    Africa
    Introduction
    Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
    Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
    Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
    Market Size and Forecast, By Country/Region, 2019 - 2031, (USD Bn)
    South Africa
    North Africa
    Central Africa
    8. Competitive Landscape
    Biogen Inc.
    Company Highlights
    Product Portfolio
    Key Developments
    Financial Performance
    Strategies
    Novartis AG
    Company Highlights
    Product Portfolio
    Key Developments
    Financial Performance
    Strategies
    Merck KGaA
    Company Highlights
    Product Portfolio
    Key Developments
    Financial Performance
    Strategies
    Sanofi S. A.
    Company Highlights
    Product Portfolio
    Key Developments
    Financial Performance
    Strategies
    Acorda Therapeutics, Inc.
    Company Highlights
    Product Portfolio
    Key Developments
    Financial Performance
    Strategies
    Teva Pharmaceuticals Industries Ltd.
    Company Highlights
    Product Portfolio
    Key Developments
    Financial Performance
    Strategies
    Bristol-Myers Squibb Company
    Company Highlights
    Product Portfolio
    Key Developments
    Financial Performance
    Strategies
    Bayer AG
    Company Highlights
    Product Portfolio
    Key Developments
    Financial Performance
    Strategies
    F.Hoffmann-La Roche AG
    Company Highlights
    Product Portfolio
    Key Developments
    Financial Performance
    Strategies
    Viatris Inc. (Mylan NV)
    Company Highlights
    Product Portfolio
    Key Developments
    Financial Performance
    Strategies
    Johnson & Johnson
    Company Highlights
    Product Portfolio
    Key Developments
    Financial Performance
    Strategies
    EMD Serono, Inc.
    Company Highlights
    Product Portfolio
    Key Developments
    Financial Performance
    Strategies
    TG Therapeutics, Inc.
    Genentech, Inc.
    Celgene Corporation
    AbbVie Inc.
    Amgen Inc.
    UCB S.A.
    Sandoz (a Novartis division)
    Ipsen S.A.
    9. Analyst Recommendations
    Wheel of Fortune
    Analyst View
    Coherent Opportunity Map
    10. References and Research Methodology
    References
    Research Methodology
    About us
    *Browse 32 market data tables and 28 figures on 'Multiple Sclerosis Therapeutics Market' - Global forecast to 2031

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook
    Cookie Settings